NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Horizon Blue Cross Blue Shield of New Jersey for its Veristrat test.

Horizon BCBS of New Jersey, which covers 3.8 million people in that state, determined as of May 10, 2016 that the test was a medically necessary benefit for patients with non-small cell lung cancer. With the decision, Veristrat is now covered for roughly 205 million people in the US, Biodesix said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.